Patents by Inventor Jenifer WIDGER

Jenifer WIDGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-AXL ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220177593
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Axl, a receptor tyrosine kinase. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer using the anti-Axl antibodies.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Applicant: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Diego Alvarado, Richard W. Gedrich, Joel Goldstein, Laura Vitale, Thomas O'Neill, Andrea Crocker, Jenifer Widger, Michael B. Murphy, Shannon Pankratz
  • AGONISTIC ANTIBODIES THAT BIND CD40
    Publication number: 20210147538
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 20, 2021
    Applicants: Celldex Therapeutics, Inc., Celldex Therapeutics, Inc.
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
    Patent number: 10941201
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: March 9, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Nucleic acids encoding agonistic antibodies that bind CD40
    Patent number: 10865244
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: December 15, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20200377606
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 18, 2017
    Publication date: December 3, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20200369768
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Agonistic antibodies that bind CD40
    Patent number: 10633444
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 28, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20190322743
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 24, 2019
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
    Publication number: 20180066053
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 18, 2017
    Publication date: March 8, 2018
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer Widger
  • CD27 AGONISTS
    Publication number: 20180044429
    Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 15, 2018
    Inventors: Tibor KELER, Joel GOLDSTEIN, Lizhen HE, Henry C. MARSH, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Laura A. VITALE, Jenifer WIDGER